SIRPA and neoplasm: Koh et al. designed an extracellular vesicle-based immune checkpoint inhibitor that achieved tumor regression by blocking CD47 with SIRPα on phagocytes, leading to more extensive CD8+ T cell infiltration in tumors [103].